Why the study?
Antithrombotic therapy could be related with nuisance bleeding, prompting investigation into whether vitreous hemorrhage is associated with specific types of antithrombotic medication in patients with atrial fibrillation.
Does dual antiplatelet or triple therapy increase the risk of vitreous hemorrhage compared to warfarin monotherapy in patients with atrial fibrillation?
Does dual antiplatelet or triple therapy increase the risk of vitreous hemorrhage compared to warfarin monotherapy in patients with atrial fibrillation?
In patients with atrial fibrillation, combining warfarin with antiplatelet agents significantly increases the risk of vitreous hemorrhage compared to warfarin monotherapy.
May warrant caution with combination antithrombotic regimens in AF; leaves open need for randomized confirmation.
PURPOSE: Antithrombotic therapy could be related with nuisance bleeding. This study investigated whether vitreous hemorrhage (VH) is associated with specific types of antithrombotic medication in patients with atrial fibrillation (AF). MATERIALS AND METHODS: In the Korean National Health Insurance Service National Sample Cohort, we identified 9352 antiplatelet/anticoagulant-treated AF patients. The occurrence of VH was compared between warfarin (n=1493) and a propensity score (PS)-matched antiplatelet group (n=1493) and between warfarin (n=1493) and a PS-matched warfarin+antiplatelet group (n=1493). RESULTS: =0.004). CONCLUSION: Dual antiplatelet or triple therapy increased the risk of VH significantly, compared to warfarin monotherapy. Considering the low efficacy of preventing ischemic stroke and high risk of bleeding, dual or triple therapy using warfarin and antiplatelet agents should be avoided to prevent VH in AF patients.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: